Drug Profile
SAR 439794
Alternative Names: SAR439794Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Sanofi
- Class Allergy immunotherapies; Food allergy immunotherapies
- Mechanism of Action Toll-like receptor 4 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Peanut hypersensitivity
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Peanut-hypersensitivity(In adolescents, In children, In adults) in USA (Sublingual, Liquid)
- 10 Mar 2020 Sanofi completes a phase I clinical trials in Peanut hypersensitivity (In children, In adults, In adolescents) in USA (Sublingual) (NCT03463135)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Peanut-hypersensitivity(In volunteers) in USA